Chicago-African-American men with clinically localized prostate cancerhave poorer overall and cancer-specific survival rates compared with similarwhite patients, according to results of a retrospective study. This disparitycan be substantially explained by differences in socioeconomic status andlower rate of surgical treatment among African-Americans.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track Designations for NMIBC
December 5th 2023The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.